Therefore, our data suggest a mechanistic basis that limiting the effect of DCA by modulation of gut microbiota or using BA sequestrants as well as targeting specific bile acid receptor signalings in macrophages may represent promising preventive and therapeutic measurements for colitis and other HFD-related inflammatory diseases. The gene discussed is NR1H4; the disease is colitis.